A Robust Pipeline
Powered by Brave Science
Areas of investigation include potential new treatments across neuroscience, endocrinology, and immunology. Our pipeline exemplifies scientific excellence that addresses unmet clinical needs.
Filter By
- All Phases
- Phase 1
- Phase 2
- Phase 3
- Study Initiating
- All Therapeutic Areas
- Endocrinology
- Immunology
- Neuroscience
- All Indications
- Alzheimer's Cognition
- Alzheimer's Psychosis
- Bipolar Mania
- Classic Congenital Adrenal Hyperplasia
- CNS Indications
- Epilepsy
- Friedreich's Ataxia
- Major Depressive Disorder
- Movement Disorders
- Obesity
- Schizophrenia
- Tardive Dyskinesia
- Women's Health
- All Modalities
- Antibody
- Gene Therapy
- Peptide
- Small Molecule
| Program (Target) | Modality | Therapeutic Area | Indication | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
| direclidine* / (M4 Agonist) | | Neuroscience | Schizophrenia | | ||
| osavampator|| / (AMPA PAM) | | Neuroscience | Major Depressive Disorder | | ||
| direclidine* / (M4 Agonist) | | Neuroscience | Bipolar Mania | | ||
| NBI-’570* (M1/M4 Agonist) | | Neuroscience | Schizophrenia | | ||
| NBI-’890 (VMAT2 Inhibitor) | | Neuroscience | Tardive Dyskinesia | | ||
| NBI-’567* ± (M1 Preferring Agonist) | | Neuroscience | Alzheimer's Cognition | | ||
| NBI-’569* (M1/M4 Agonist) | | Neuroscience | Alzheimer's Psychosis | | ||
| NBI-’675 (VMAT2 Inhibitor) | | Neuroscience | CNS Indications | | ||
| NBI-’355 (Nav1.2/1.6 Inhibitor) | | Neuroscience | Epilepsy | | ||
| NBIP-’1435 (CRF1 Antagonist) | | Endocrinology | Classic Congenital Adrenal Hyperplasia | | ||
| NBIP-’2118 (CRF2 Agonist) | | Endocrinology | Obesity | | ||
| NBIP-’1968 (Triple G Agonist) | | Endocrinology | Obesity | | ||
| NBIM-’1112 (Undisclosed) | | Immunology | Undisclosed | | ||
| NBIM-’1008 (Undisclosed) | | Immunology | Undisclosed | | ||
| NBIM-’1748 (Undisclosed) | | Immunology | Undisclosed | | ||
| NBIB-’223 (Frataxin) | | Neuroscience | Friedreich's Ataxia | | ||
| NBI-’737 (Undisclosed) | | Endocrinology | Undisclosed | | ||
Neurocrine Biosciences has global rights unless otherwise noted.
Investigational therapies are not approved for use in any country.
*Licensed from Nxera Pharma.
±Nxera Pharma has retained rights in Japan; Neurocrine Biosciences may opt-in to a 50:50 cost and revenue share upon certain development events.
॥Takeda Pharmaceutical Company Limited has retained rights in Japan.
CRF2 = Corticotropin Releasing Factor 2; TG = Neurocrine Proprietary GIP-GLP-1-Preferring Triple Agonist” (“Light” on Glucagon Activity); CRF1 = Corticotropin Releasing Factor 1; M1 = M1 Muscarinic Receptor; M4 = M4 Muscarinic Receptor; VMAT2 = Vesicular Monoamine Transporter; CNS = Central Nervous System; Nav = Sodium Channel; AMPA PAM = alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid Positive Allosteric Modulator
-
Investor Relations
Learn More -
Clinical Studies
Check Out What We're Studying -
Career Opportunities
Work With Us